Evidence map›Paper›PMID 26291973›Full record

ArticlePloS one2015

Evaluation of Left Ventricle Function by Regional Fractional Area Change (RFAC) in a Mouse Model of Myocardial Infarction Secondary to Valsartan Treatment.

Laura Castiglioni, Francesca Colazzo, Lucia Fontana, Gualtiero I Colombo, Luca Piacentini, Elisa Bono, Giuseppina Milano, Serena Paleari, Annamaria Palermo, Uliano Guerrini and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Signaling Pathways and Potential Therapeutic Strategies in Cardiac Fibrosis.International journal of molecular sciences · 2023
    Review
  6. Review
  7. Article
  8. Impact ofCells · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Laura CastiglioniDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
Francesca ColazzoCentro Cardiologico Monzino IRCCS, Milan, Italy.
Lucia FontanaCentro Cardiologico Monzino IRCCS, Milan, Italy.
Gualtiero I ColomboCentro Cardiologico Monzino IRCCS, Milan, Italy.
Luca PiacentiniCentro Cardiologico Monzino IRCCS, Milan, Italy.
Elisa BonoCentro Cardiologico Monzino IRCCS, Milan, Italy.
Giuseppina MilanoCentro Cardiologico Monzino IRCCS, Milan, Italy.
Serena PaleariDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
Annamaria PalermoDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
Uliano GuerriniDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
Elena TremoliDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy; Centro Cardiologico Monzino IRCCS, Milan, Italy.
Luigi SironiDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy; Centro Cardiologico Monzino IRCCS, Milan, Italy.
Centro Cardiologico Monzino · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimLeft ventricle (LV) regional fractional area change (RFAC) measured by cardiac magnetic resonance (CMR) allows the non-invasive localization and quantification of the degree of myocardial infarction (MI), and could be applied to assess the effectiveness of pharmacological or regenerative therapies. Here we investigate the ability of RFAC to identify regional dysfunction and discriminate the effect of pharmacological treatment with valsartan, a selective antagonist of angiotensin II type 1 receptor, in a model of MI. METHODS AND

resultsC57BL/6N mice, undergoing coronary artery ligation, were divided into two groups: untreated (MI) or treated with valsartan (MI+Val). Sham-operated mice were used as a control. Cardiac dimensions and function were assessed at baseline, 24 hours, 1 and 4 weeks post surgery by CMR and echocardiography. At sacrifice histology and whole-genome gene expression profiling were performed. RFAC was able to detect significant differences between treatment groups whereas the global ejection fraction was not. RFAC showed greater loss of regional contraction in remote non-infarcted myocardium in MI group than in MI+Val group. Consistently, in the same region MI+Val mice showed reduced myocyte hypertrophy, fibroblast proliferation, and fibrosis and modulation of target genes; in addition, left atrium volumes, appendage length and duct contraction were preserved.

conclusionIn this study, RFAC effectively estimated the degree of systolic dysfunction and discriminated the regions preserved by pharmacological treatment. RFAC index is a promising tool to monitor changes in LV contraction and to assess the effectiveness of therapeutic regimens in clinical settings.

Indexed as

Angiotensin II Type 1 Receptor BlockersAnimalsDisease Models, AnimalEchocardiographyFemaleGene Expression ProfilingMagnetic Resonance ImagingMiceMice, Inbred C57BLMyocardial InfarctionMyocardiumValsartanVentricular Function, LeftVentricular RemodelingAngiotensin II Type 1 Receptor BlockersValsartan

Identifiers

PMID26291973
PMCPMC4546366
OpenAlexW1891391801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.